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A B S T R A C T
Post-transplant lymphoproliferative disorders (PTLDs) represent the most severe complication of both
solid organ and hematopoietic stem cell transplantation. The Epstein–Barr Virus (EBV) is the main driver
of PTLD, particularly those occurring early after transplantation. EBV-driven malignancies are associ-
ated with selective expression of latent viral proteins, but uncontrolled lytic replication may favor early
phases of cell transformation. Besides immunodepression, persistent immune activation and chronic in-
ﬂammation play an important role in both virus reactivation and expansion of EBV-infected B cells. EBV-
induced immortalization requires the expression of telomerase. TERT, the rate-limiting component of
the telomerase complex, is central in the switch from the lytic to the latent viral program, and TERT in-
hibition induces the EBV lytic cycle and cell death. Immunotherapy and combination of EBV lytic cycle
inducers with antiviral drugs are promising strategies to improve the treatment of PTLD patients. This
review is aimed at providing an update on the intriguing association between EBV and PTLD, mainly fo-
cusing on cases arising after kidney and liver transplantation, which account for the vast majority of
transplants.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The term ‘post-transplant lymphoproliferative disorder’ (PTLD)
was ﬁrst introduced in 1984 by Starzl [1]. PTLD represents the most
severe complication of both solid organ (SOT) and hematopoietic
stem cell transplantation (HSCT) and occurs in 1–20% of post-
transplant patients [2]. SOT is an increasingly usedmedical procedure
for treating otherwise fatal end-stage organ diseases. According to
the WHO, more than 114,690 transplants were performed world-
wide in 2012, 1.8% more than in 2011, but still less than 10% of the
global need. The two most frequently transplanted organs were
kidney (68%) and liver (21%) and most transplants were from de-
ceased donors (58% kidney and 82% liver) [3]. Continuing
improvements in the eﬃcacy of anti-rejection drugs have greatly
contributed toward prolonging the long-term survival of trans-
plant recipients; however, life-long use of immunosuppressive drugs
increases the risk of opportunistic diseases and malignancies. The
frequency of cancer increases during immunosuppression; after 10
years of continued immunosuppressive therapies, approximately 20%
of transplanted patients have a diagnosis of cancer, a risk 2- to 5-fold
higher than in the general population [4,5].
Among malignancies occurring in transplanted persons, the in-
cidence of PTLD varies according to several risk factors, such as type
of transplant, age of recipient, and duration and type of immuno-
suppression treatment [6–8]. The entire PTLD spectrum includes
lymphoproliferative entities varying from reactive hyperplasia toma-
lignant lymphoma. According to the latest WHO classiﬁcation in
2008, PTLD is classiﬁed into four basic histological types: (1) early
lesions; (2) polymorphic (P-PTLD); (3) monomorphic (M-PTLD); and
(4) classical Hodgkin lymphoma (HL) [6]. Early lesions consist of
benign polyclonal lymphoproliferations, which mostly regress with
reduction of the immunosuppressive regimen. P-PTLD is com-
posed of a mixed population of immunoblasts, plasma cells and
intermediate-sized lymphoid cells. Most P-PTLDs are Epstein–
Barr Virus (EBV)-positive and arisewithin one year of transplantation.
M-PTLD are mainly of B-cell origin. Most M-PTLDs are Non-Hodgkin
Lymphomas (NHL), mainly Diffuse Large B-cell lymphoma (DLBCL),
although sporadic cases of Burkitt’s lymphoma (BL) do occur. Almost
all cases display a clonal pattern of IGH gene rearrangement. M-PTLD
is thought to arise from early lesions and P-PTLD. Moreover, within
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theM-PTLD group, EBV-positive lymphomas arise earlier after trans-
plantation than EBV-negative ones [2,6–8]. Regardless of their
histological type, PTLDs can also be deﬁned as early- or late-onset
if the diagnosis is made within or after 12 months from transplan-
tation, respectively [2,9].
PTLD development following SOT is estimated from 1% to 20%,
with the highest incidence for intestinal and multivisceral trans-
plants (5%–20%), followed by lung and heart transplants (2–10%)
and the lowest for renal and liver transplants (1%–5%) [2]. However,
since the vast majority of transplanted organs are kidney (68%) fol-
lowed by liver (21%), we focused our attention on the role of EBV
in the onset of PTLD after kidney and liver transplantation. Increas-
ing knowledge about the pathogenesis of PTLD will open the door
to new therapeutic strategies.
PTLD incidence after kidney or liver transplant
The PTLD incidence in kidney and liver transplant reported in
the last 5 years (2010–2015) is shown in Table 1. In an Italian cohort
of 7217 kidney transplant recipients, 52 patients developed PTLD,
with a cumulative incidence of 0.7% [10]. A slightly higher cumu-
lative incidence of 2.9% was reported in a Spanish cohort [11].
Similarly, the PTLD frequency described by Yoon et al. [12] was 1.9%.
In a larger US cohort of 156,740 kidney transplant recipients, 762
(0.5%) cases of PTLD were identiﬁed during a 20-year follow-up
(1987–2007). The incidence rates of PTLD at 5 and 10 years post-
transplant were 0.7% and 1.4%, respectively [13]. Taking into account
the timing of PTLD onset, most early-PTLD (n = 361, within the ﬁrst
2 years after transplantation) were monomorphic (48% vs. 42% poly-
morphic and 10% of unknown pathology) and of B-cell origin (72%
vs. 4% T-cell, 24% unknown). Late-PTLD (n = 401, more than 2 years
after transplant) was even more likely to be of monomorphic pa-
thology (56% vs. 31% polymorphic and 13% unknown) and
predominantly of B-cell, but with a higher proportion of T-cell origin
(64% B-cell vs. 10% T-cell, 26% unknown) [13]. Data obtained from
this large cohort, including cases from the Scientiﬁc Registry of Trans-
plant Recipients, are of particular importance since they identiﬁed
a more reliable incidence of PTLD onset (in general and also in par-
ticular, looking at both early- and late-onset) than other smaller
cohorts, conﬁrming that PTLD remains an important source of mor-
bidity associated with solid organ transplantation. In a cohort of
137,939 primary kidney transplants, 913 (0.7%) patients devel-
oped PTLD, with an incidence of 0.4% at 1 year (early-onset) and
0.5%, 0.9% and 1.9% at 3, 5 and 10 years (late-onset), respectively
[14].
In one study, the incidence of PTLDwas 0.8% (17/2192) for kidney
transplant recipients and 0.8% (16/2067) for liver transplant recipi-
ents; 93% (14/15) of PTLDs in the former were of late-onset, while
50% (8/16) of PTLDs in the latter were of early-onset and 50% (8/
16) of late-onset [15]. As regards liver transplant, Marino et al. [16]
described the experience of a single center in which a total of 826
transplants in 766 recipients was performed over a period of 20
years. Of these, 10 patients developed PTLD with a cumulative in-
cidence of 1.2%, with two cases (20%) of early-onset. A 1.3% of PTLD
incidence was found by Ettorre et al. [17] in a cohort of 1675 liver
transplants from various Italian centers. Similarly, in an Argentin-
ean cohort of 1621 liver transplant recipients, 27 patients developed
PTLD (1.7%); early-onset disease was identiﬁed in 7 patients (27%)
and late-onset in 19 (73%) [18], and yet another study reported a
2.3% (15/658) incidence of PTLD, of which 33% occurred during the
ﬁrst year after liver transplantation [19]. In a recent study of a total
of 444 liver transplants, PTLD occurred in 16 (3.6%) patients, most
being of early-onset (11/16, 69%) [20]. Three patients (0.9%) devel-
oped PTLD out of 323 adult patients who underwent liver transplant
and all 3 were cases of late-onset [21]. Overall, as already re-
ported in the literature [2,7,8], the incidence rates of PTLD reported
in our review were quite broad (0.5–2.9 in kidney and 0.8–3.6 in
liver), probably due to the different sizes of the examined cohorts
(Table 1).
EBV-related PTLD
EBV is a member of the γ-herpesvirus family which usually es-
tablishes a lifelong asymptomatic infection in immunocompetent
hosts. Most individuals contract EBV infection in early adulthood
[22] and primary EBV infection may sometimes result in a self-
limiting disease, known as infectious mononucleosis, due to an
abnormal EBV-speciﬁc immune response. Host immunity plays a
crucial role in controlling EBV infection and the virus has evolved
an elegant strategy which allows EBV to exploit B-cell differentia-
tion to ﬁnally establish an asymptomatic latency in resting memory
B lymphocytes [22]. In post-transplant patients, impaired
immunosurveillance against EBV may favor the onset of EBV-
associated diseases, such as PTLD [23]. PTLD is commonly of B-cell
origin [2,7,22,24]. Overall, 60–80% of total PTLD cases are found to
be EBV-positive [15,25] and the incidence of EBV positivity changes
slightly according to PTLD type, being higher in early than in late
cases. The EBV genome is found in more than 90% of PTLD during
the ﬁrst year after transplantation [26]. A comprehensive search for
cases of liver transplantation disclosed EBV infection in 80% of PTLD
Table 1
PTLD incidence after kidney or liver transplantation.
Organ Reference Country Population
no.
PTLD
no. (%)a
Early-onset
no. (%)
Late-onset
no. (%)
Kidney [10] Italy 7217 52 (0.7) – –
[11] Spain 2011 60 (2.9) – –
[12] Korea 1489 28 (1.9) 5 (18) 23 (82)
[13] USA 156,740 762 (0.5) 361 (47)b 401 (53)
[14] USA 137,939 913 (0.7) – –
[15] Korea 2192 17 (0.8) 8 (50) 8 (50)
Liver [12] Korea 2067 16 (0.8) 1 (7) 14 (93)
[16] Italy 766 10 (1.2) 2 (20) 8 (80)
[17] Italy 1675 22 (1.3) – –
[18] Argentina 1621 27 (1.7) 7 (27) 19 (73)
[19] Hong Kong 658 15 (2.3) 5 (33) 10 (67)
[20] Taiwan 444 16 (3.6) 11 (69) 5 (31)
[21] Japan 323 3 (0.9) 0 (0) 3 (100)
Search strategy was: Post-transplant lymphoproliferative disorder [All Fields] OR PTLD [All Fields] AND incidence [All Fields] AND (kidney [All Fields] OR liver [All Fields])
AND (early-onset [All Fields] OR late-onset [All Fields]) AND (“2010/01/01”[PDAT] : “2015/03/31”[PDAT]) AND English [lang].
a Cumulative incidence for PTLD onset.
b Within two years after transplantation.
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and 91% and 66% at early- and late-onset EBV-positive, respective-
ly [9]. Notably, 88% of PTLD developed very early (within the ﬁrst
month) after SOT has been found to be EBV-positive [27]. EBV has
also been found in 52% of patients with late-onset PTLD after kidney
transplant [28]. Similar frequencies were found in a mixed cohort
of SOT with an overall 89% of PTLD (13/19) EBV-positive, being 100%
(2/2) at early- and 65% (11/17) at late-onset [29]. Sixty-eight per
cent (38/56) of PTLD cases were found to be EBV-positive, 91% (10/
11) early-onset and 62% (28/45) late-onset [30]. Thus, the majority
of PTLD cases arising in both kidney and liver transplant patients
are EBV-associated, more than 90% of cases being of early-onset
(Table 2).
Mechanisms for EBV-driven PTLD
EBV is associated with both B-cell and epithelial-cell malignan-
cies. Like other γ-herpesviruses, EBV has both latent and lytic
programs in its life-cycle. Since lytic EBV replication triggers the death
of infected cells, tumors require the expression of latent pro-
grams. Latent proteins include nuclear antigens (EBNA-1, -2, -3A,
-3B, -3C), leader protein (LP), and latent membrane proteins (LMP-
1, -2A, and -2B). LMP-1 is the main oncogenic protein of EBV and
is essential for EBV-driven tumorigenesis [23,26]. It is expressed in
NHL, except BL, and in HL. Functionally, LMP-1 provides both growth
and differentiation signals to B cells. Acting like CD40, a member
of the tumor necrosis factor receptor (TNFR) superfamily, LMP-1 ac-
tivates several downstream signaling pathways, which contribute
to the expression of anti-apoptotic proteins (e.g., BCL-2 and A20)
and cytokines, such as IL-1 and CD40L [22,31].
Like most cancers, EBV-associated malignancies require induc-
tion of telomerase activity. Telomerase, a ribonucleoprotein complex
containing an internal RNA template (TR) and a catalytic protein with
telomere speciﬁc reverse transcriptase (TERT) activity, extends the
telomeres at the ends of eukaryotic chromosomes, thus prevent-
ing cell senescence and apoptosis. While TR is constitutively present
in normal and tumor cells, TERT is the rate-limiting component of
the telomerase complex, and its expression correlates with
telomerase activity. TERT activity is repressed in somatic tissues,
but both TERT expression and telomerase activity are elevated in
most human tumors [reviewed in [32]]. In EBV-infected primary B
lymphocytes, activation of TERT occurs concomitantly with the in-
duction of latent EBV proteins and down-regulation of EBV lytic gene
expression. LMP-1 is the main driver of EBV-induced immortaliza-
tion, since it activates TERT at transcriptional level via the nuclear
factor kappa B (NF-κB) andMAPK/ERK1/2 pathways [33,34]. In turn,
TERT expression, via the NOTCH2/BATF pathway, negatively affects
the expression of BZLF-1, the master regulator of the viral lytic cycle,
thereby favoring the induction and maintenance of EBV latency, a
prerequisite for EBV-driven transformation [35]. In contrast, TERT
silencing by speciﬁc siRNA or short-hairpin (sh)RNA induces the ex-
pression of BZLF-1, EA-D, and gp350 EBV lytic proteins and triggers
a complete lytic cycle [33,36].
Although latency programs predominate in EBV-driven tumors,
some recent data have suggested that the uncontrolled viral lytic
cycle has some pathogenic importance, at least in the early phase
of transformation. In fact, lymphoblastoid B-cell lines obtained with
lytic-defective EBV strains have been shown to be less effective in
inducing EBV-positive lymphoproliferations in SCID mice, an effect
due to the lower production of the B-cell growth promoting factors
IL-6, cIL-10, and vIL-10, dependent on BZLF-1, the main EBV lytic
transactivator [37]. Moreover, several EBV lytic proteins have also
been shown to favor immune evasion by inhibiting the synthesis
of Interferon (IFN)-γ and suppressing CD8 cytotoxic T cells [38] and
to contribute to tumorigenesis by promoting angiogenesis [39].
Besides immune depression, persistent immune activation/
chronic inﬂammation may also play a key role in PTLD development
[23]. Scientists have identiﬁed parallels between cancer and infec-
tious disease [40]. Indeed, in cancer as in infectious diseases, the
release of microbial pathogen-associatedmolecular patterns (PAMPs),
such as lipopolysaccharide (LPS), 16S ribosomal DNA, CpG DNA, and
endogenous damage-associated molecular patterns (DAMPs), such
as mitochondrial DNA (mtDNA), by engaging the extra- or intra-
cellular domain of Toll-like receptors (TLRs) may initiate a complex
signal transduction cascade which, via the NF-κB pathway, ulti-
mately leads to the release of pro-inﬂammatory cytokines, such as
IL-6, IL-10, IFN-α and tumor necrosis factor (TNF), causing chronic
inﬂammation [23]. This chronic stimulation may activate EBV rep-
lication and/or contribute to the polyclonal expansion of EBV-
positive cells.
Chronic B-cell hyperactivation is driven by overproduction of
B-cell stimulatory cytokines, such as IL-6, IL-10, IFN-α and TNF
[41–43]. In the context of immunosuppression associated with
Human Immunodeﬁciency Virus (HIV)-1 infection, it has been dem-
onstrated that serum levels of these B-cell stimulatory cytokines
and other molecules, such as soluble CD27 and sCD30, signiﬁ-
cantly increase 1–5 years prior to diagnosis of systemic AIDS-NHL
[44,45]. Elevated serum levels of IL-6 have also been observed 1–3
years prior to the onset of AIDS-NHL, thus supporting the role of
IL-6-driven B-cell stimulation in the development of these lym-
phomas [45]. TLR9 substantially suppresses the expression of BZLF-
1, by histone modiﬁcation in acute EBV infection ex vivo and in
latently BL cells in vitro, suggesting that immune activation can also
promote EBV-driven lymphomagenesis by suppressing the viral lytic
cycle [46]. In addition, HIV-infected patients with high levels of EBV
present higher levels of pro-inﬂammatory cytokines (IL-6, IL-10, TNF-
α) and PAMPs (LPS, 16S rDNA) than patients with low EBV levels.
EBV load is also closely correlated with the percentage of acti-
vated B cells [47]. Although these ﬁndings deal with EBV dynamics
Table 2
Incidence of EBV-positive PTLD.
Reference Organ PTLD patients (EBVa) EBV-positive PTLD
Overall
no. (%)
Early-onset
no. (%)
Late-onset
no. (%)
[9] Liver 231 (148) 118 (80) 76 (91) 42 (66)
[15] SOT 43 (40) 29 (73) – –
[25] Kidney 500 (362) 249 (69) – –
[27] SOT 355 (204) – 179 (88)b –
[28] Kidney 52 (52) – – 18 (52)
[29] SOT 19 (19) 13 (68) 2 (100) 11 (65)
[30] Kidney 80 (56) 38 (68) 10 (91) 28 (62)
Search strategy was: Post-transplant lymphoproliferative disorder [All Fields] OR PTLD [All Fields] AND incidence [All Fields] AND (kidney [All Fields] OR liver [All Fields])
AND (early-onset [All Fields] OR late-onset [All Fields]) AND EBV [All Fields] (“2010/01/01”[PDAT] : “2015/03/31”[PDAT]) AND English[lang].
a Number of patients tested for EBV.
b Ultra-early onset within the ﬁrst month.
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in HIV-infected patients, the concept that B-cell activationmay favor
expansion of EBV-infected B cells can also be applied to the context
of immunosuppression associated with transplantation (Fig. 1).
This hypothesis is also supported by the evidence that in-
creased EBV-DNA load is a strong predictive risk factor for the onset
of PTLD. Assessment of EBV viremia is of clinical importance in trans-
plant recipients, thus representing a useful tool for early diagnosis
and monitoring of patients at high risk for PTLD [48]. EBV load may
also represent a useful marker to appropriately modulate immu-
nosuppressive therapy and initiate pre-emptive or antitumor therapy
[49]. The strong correlation between EBV-DNA levels and the
numbers of circulating EBV-carrying cells suggested that in-
creased EBV-DNA is probably due to increased numbers of EBV
infected cells rather than increased numbers of viral genomes per
cell [50]. A progressive switch from the restricted pattern of latency
to broader patterns of EBV gene expression associated with lytic rep-
lication has been shown during the post-transplant period in
peripheral blood cells [51]. Although possible interference due to
viral DNA released from damaged cells cannot be excluded [52], EBV-
DNA in serum/plasma may represent EBV lytic replication. Several
studies have demonstrated that PTLD is accompanied by a signif-
icant increase in EBV levels in peripheral blood mononuclear cells
(PBMC) [50,53–58] and in whole peripheral blood [59–63]. In par-
ticular, increased levels of EBV-DNA in serum or whole blood have
been found to be predictive of PTLD onset in post-transplant pa-
tients [62–64]. Nevertheless, high EBV-DNA alone is not always
predictive of impending PTLD [51,65,66]. Rapidly increasing EBV-
DNA levels rather than a stably elevated EBV-DNA load seems to
be a more reliable marker of PTLD, so that serial monitoring is im-
portant to identify patients at risk of disease [67,68].
Although real-time PCR is widely used for precise and frequent
monitoring of EBV load, uncertainties still exist on the choice of the
most appropriate starting biological material (serum/plasma, pe-
ripheral blood mononuclear cells or whole blood), the DNA
puriﬁcationmethod, the EBV-DNA fragment to be ampliﬁed, the clin-
ical specimens to be used, and the deﬁnition of cut-off values of
clinical importance. Unfortunately, deﬁning a cut-off value seems
to be quite diﬃcult, since several studies (2000–2015) have re-
ported varying values of EBV load [50,52,55–64,69,70] (Table 3).
It should be noted that, while EBV-DNA in plasma may reﬂect
the lytic cycle of EBV, which can occur mainly in the early phase,
the increased levels of EBV in PBMC usually reﬂect the expansion
of EBV-infected cells, a crucial step for PTLD development. In ad-
dition, a key step in EBV-related tumorigenesis is the maintenance
of cell replicative potential due to activation of TERT by the viral
protein LMP-1. The choice of biological samples (plasma or cells)
to measure EBV level combined with a search for additional markers
(e.g., lytic vs. latent viral protein expression, TERT level) will in-
crease the value of EBV proﬁling in predicting the onset of PTLD.
Immunologic parameters may be very informative in this respect.
In EBV-seronegative children who had undergone liver transplan-
tation, the occurrence of high EBV load without PTLD development
was in fact associated with a concomitant increase in EBV-speciﬁc
cellular responses [71]. These ﬁndings suggest that the combined
assessment of EBV DNA load and EBV-speciﬁc T-cell count could
allow a more precise prediction of the risk of PTLD development.
Strategies for treatment of EBV-driven PTLD
The primary goal in treatment of PTLD is to cure the disease, while
concomitantly preserving graft functions. Early diagnosis and treat-
ment are mandatory to avoid PTLD-related morbidity andmortality.
There is no consensus treatment model for the optimal manage-
ment of PTLD due to its clinico-pathologic heterogeneity. Strategies
to prevent EBV-associated PTLD usually aim at partially recover-
ing immune surveillance and involve reduction of immune
suppression to allow restoration of speciﬁc immunity and control
Fig. 1. Pathogenetic mechanisms of early onset EBV-related PTLD. PAMPs and DAMPs, through TLRs, promote the release of pro-inﬂammatory cytokines, which in turn ac-
tivate EBV lytic cycle. At early stage of disease, lytic replication of EBV leads to increased number of infected cells. Moreover, B-cell activation, due to persistent inﬂammation/
immune activation, may also favor expansion of EBV-infected B cells, leading to a signiﬁcant increase in EBV load in peripheral blood mononuclear cells, a crucial step for
PTLD development. Along with infection, the oncogenic LMP-1 viral protein transcriptionally activates TERT, the catalytic component of telomerase activity, which in turn
blocks lytic viral replication. EBV-infected B cells expressing LMP-1 and cellular TERT protein are prone to transformation. Levels of circulating products involved in inﬂammation/
activation, as well as increased EBV-DNA levels, may predict PTLD onset. Circulating TERT, released from TERT-positive cells, may be useful in monitoring disease outcome.
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of EBV-infected proliferating cells [8,49]. For EBV-induced PTLD, re-
duction of immunosuppression appears to be effective in 23–50%
of cases [72], although the difference in response seems to be related
to the degree of reduction of immunosuppression or to the time
of disease onset. Patients with early-onset disease have better out-
comes with reduced immunosuppression than those with late-
onset PTLD [72].
Immunotherapy with monoclonal antibodies, particularly anti-
CD20 antibody (rituximab), is the ﬁrst line of treatment for patients
who do not respond to reduction or discontinuation of immuno-
suppression. In several studies, rituximab administered for treatment
purposes yielded a 40–68% response rate [73–75]. In the pre-
emptive setting, it has been demonstrated that the anti-CD20
antibody can prevent EBV-associated PTLD in about 90% of cases
[76].
A more targeted approach for the prevention and treatment of
EBV-driven PTLD is based on selective restoration of EBV immuni-
ty by the adoptive transfer of EBV-speciﬁc cytotoxic T cells (CTLs).
The conventional protocol adopted to generate these effectors is
based on the use of EBV-immortalized lymphoblastoid cell lines as
antigen-presenting cells which can eﬃciently stimulate EBV-
speciﬁc T-cells which, in turn, can be ﬁnally transferred to patients
after a 3- to 4-week period of expansion ex vivo [77]. The most bril-
liant results were obtained in the pre-emptive setting, whereas the
clinical beneﬁt in patients with overt PTLD is still unsatisfactory in
a proportion of cases. One of the main limitations of the applica-
bility of this immunotherapeutic strategy is the often urgent need
to have adequate numbers of EBV-speciﬁc CTLs in a very short time
after PTLD diagnosis in order to counteract the rapid progression
of the disease. On these grounds, protocols have recently been de-
veloped to generate CTLs rapidly by overnight stimulation of donor
mononuclear blood cells with EBV-speciﬁc peptides and selection
of antigen-speciﬁc T cells by IFN-γ surface capture assays [78].
However, despite these advances, EBV-speciﬁc CTLs are still diﬃ-
cult to use in clinical practice.
Antiviral agents as a therapeutic strategy for treating PTLD are
frequently used and have also been proposed as pre-emptive therapy.
In a pediatric liver transplant study, the incidence of PTLD fell from
10% to 5% among patients who received prophylactic ganciclovir [79].
The use of ganciclovir in children and adults after kidney trans-
plantation has been associated with a reduction of risk up to 83%
of PTLD, especially during the ﬁrst year post-transplant [80]. The
beneﬁt after onemonth of treatment gave a 38% risk reduction. These
data are promising, but thorough validation in prospective ran-
domized clinical trials is needed. In one cohort of children with liver
transplants, valganciclovir was used to treat transplant patients
showing detectable EBV-DNA. Data showed that long-term treatment
(8months) achieved undetectable EBV-DNA in 47.6% of patients, 60%
of whom maintained response when off therapy [8,81].
However, it should be stressed that the pro-drug ganciclovir is
activated by the lytic viral protein timidine kinase, i.e., it is not active
in EBV-associated tumors in which only latent proteins are ex-
pressed. This means that antiviral agents, such as ganciclovir, are
not active against latently EBV-infected cells, although these drugs
can decrease the rate of EBV replication, thus limiting the spread
of EBV within the host. There is increasing interest in developing
strategies potentially able to eﬃciently reactivate EBV lytic gene ex-
pression in latently infected tumor cells to treat overt EBV-associated
malignancies, as lytic infection promotes the death of EBV- posi-
tive tumor cells both in vitro and in vivo [82–85]. Triggering EBV
lytic replication in vivo may be particularly effective and therapeu-
tically important as it promotes immune recognition of viral antigens,
which further enhances the killing of tumor cells by immune ef-
fectors. In addition, lytic cycle induction enables the expression of
viral kinases, sensitizing the cells to antiviral drugs [86]. Several che-
motherapeutic drugs are known to trigger EBV replication, including
5-ﬂuorouracil, methotrexate, doxorubicin, and several histone
deacetylase inhibitors [84,85,87,88]. Notably, combined treatment
with arginine butyrate and ganciclovir signiﬁcantly improves the
clinical response in patients with refractory EBV-associated lym-
phoid malignancies [89]. Combination of antivirals with lytic cycle
inducers is thus emerging as a highly promising strategy in treat-
ing EBV-driven tumors. In view of the role of TERT in regulating the
switch from latent to lytic infection, a strategy aimed at inhibiting
TERT in combination with antiviral drugs appears particularly at-
tractive. As a promising future therapeutic perspective, it is worth
mentioning that TERT silencing in vitro by short hairpin RNA has
been shown to induce the expression of EBV lytic proteins and to
trigger a complete lytic cycle, resulting in cell death [36]. Notably,
ganciclovir markedly enhances the apoptotic effect induced by TERT
inhibition in EBV-positive lymphoblastoid cell lines, suggesting that
combining antiviral drugs with inhibitors of TERT expression/
activity may constitute an attractive therapeutic strategy to be
investigated in patients with EBV-related malignancies, including
PTLD (Fig. 2).
Conclusions
PTLD represents an infrequent but serious complication of both
hematopoietic stem cell and solid organ transplantation. Most
cases, particularly those arising early after transplantation, are as-
sociated with EBV infection. These uncontrolled EBV-driven
lymphoproliferations are the best examples of the critical role played
by host immunity in controlling EBV infection. In the setting of
Table 3
EBV-DNA levels and PTLDs.
References Cases Sources Method of EBV quantiﬁcation EBV-DNA levels
[50] 8 adult PTLD patients PBMCa In-house quantitative competitive PCR >2000 copies/106 PBMC
[55] 8 adult PTLD patients PBMC In-house semi-quantitative nested PCR >200 copies/105 PBMC
[56] 11 adult at PTLD diagnosis PBMC In-house real-time PCR >1000 copies/106 PBMC
[58] 5 adult PTLD patients PBMC In-house real-time PCR >300 copies/105 PBMC
[57] 3 pediatric PTLD patient PBMC and plasma In-house quantitative PCR >1000 copies/105 PBMC and
>500 copies/ml
[64] 57 transplant patients Serum In-house real-time PCR >50,000 copies/ml high risk of PTLD
[69] 1 pediatric PTLD patient Plasma In-house real-time PCR >200 copies/ml
[70] 3 pediatric PTLD patient Serum In-house nested PCR >5000 copies/ml
[52] 6 adults at PTLD diagnosis Whole blood In-house quantitative competitive PCR >1000 copies/ml
[59] 264 pediatric transplant patients Whole blood In-house real-time PCR >30,000 copies/ml
[60] 6 adults at PTLD diagnosis Whole blood In-house quantitative competitive PCR >2000 copies/ml
[61] 2 pediatric PTLD patient Whole blood In-house semi-quantitative nested PCR >30,000 copies/ml
[62] 53 transplant patients Whole blood In-house real-time PCR >100,000 copies/ml high risk of PTLD
[63] 41 transplant patients Whole blood Commercially available real-time PCR >100,000 copies/ml high risk of PTLD
a Peripheral blood mononuclear cells.
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iatrogenic immune suppression which characterizes transplant pa-
tients, EBV-infected lymphoid cells may proliferate and expand,
thanks to the driving force of several EBV antigens expressed during
latency, mainly LMP-1. Nevertheless, recent evidence indicates that
factors released during early lytic replication of the virus may also
contribute to the development of PTLD, together with still poorly
deﬁned additional microenvironmental factors. From a preventive
and therapeutic point of view, anti-CD20 antibodies alone or in com-
bination with chemotherapy and adoptive infusion of EBV-speciﬁc
CTLs are useful and effective approaches, although PTLD contin-
ues to show high mortality from both refractory disease and
complications of treatment. Cellular therapies targeting EBV anti-
gens should be streamlined to achieve more timely and broadly
applicable treatment of this still challenging disease. New and prom-
ising EBV-targeted therapeutic approaches are emerging, including
pathway-driven therapies and strategies aimed at inducing EBV lytic
replication in combination with antiviral drugs.
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